Transitional cell carcinoma metastatic – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 11:25:29 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Transitional cell carcinoma metastatic – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Phase 1/2 Evaluation of Zilovertamab Vedotin in PD-1/L1 Refractory Locally Advanced or Metastatic Urothelial Carcinoma https://clinicaltrials.eu/trial/phase-1-2-evaluation-of-zilovertamab-vedotin-in-pd-1-l1-refractory-locally-advanced-or-metastatic-urothelial-carcinoma/ Fri, 05 Jun 2026 10:55:26 +0000 https://clinicaltrials.eu/trial/phase-1-2-evaluation-of-zilovertamab-vedotin-in-pd-1-l1-refractory-locally-advanced-or-metastatic-urothelial-carcinoma/ This clinical trial is focused on studying a type of cancer called urothelial carcinoma, which affects the bladder and other parts of the urinary system. The study is specifically looking at cases where the cancer is either locally advanced or has spread to other parts of the body, known as metastatic urothelial carcinoma. The trial is testing a new treatment called Zilovertamab vedotin, which is given as a solution through an intravenous infusion. This treatment is being tested on patients whose cancer has not responded to previous treatments that target proteins called PD-1 or PD-L1.

The purpose of the study is to understand how safe and tolerable the new treatment is for patients, as well as to see how well it works in reducing the size of the cancer. Participants in the study will receive the investigational treatment, and their response to the treatment will be monitored over time. The study will also look at how long any positive effects of the treatment last.

Throughout the study, researchers will keep track of any side effects experienced by participants and whether these side effects lead to stopping the treatment. The study aims to gather important information that could help in developing new treatment options for people with this type of cancer. The trial is expected to continue until early 2028.

]]> Avelumab Maintenance in Patients with Metastatic Urothelial Carcinoma After Second-Line Platinum-Based Chemotherapy https://clinicaltrials.eu/trial/avelumab-maintenance-in-patients-with-metastatic-urothelial-carcinoma-after-second-line-platinum-based-chemotherapy/ Tue, 02 Jun 2026 09:56:37 +0000 https://clinicaltrials.eu/trial/avelumab-maintenance-in-patients-with-metastatic-urothelial-carcinoma-after-second-line-platinum-based-chemotherapy/ This clinical trial is studying metastatic urothelial carcinoma, a cancer that starts in the lining of the urinary tract and has spread to other parts of the body. The treatment being tested is avelumab, given by vein, as maintenance treatment, which means it is used after earlier cancer treatment to help keep the disease under control. The study is looking at whether avelumab can help people whose cancer has already responded to or stayed stable after platinum-based chemotherapy, a common type of cancer drug treatment that uses medicines containing platinum.

In this trial, one group receives avelumab and the other group receives best supportive care, which means care focused on relieving symptoms and keeping the person as comfortable as possible. The purpose of the study is to see whether avelumab can help control the cancer better than supportive care alone. During the study, treatment is given over time, and doctors follow the course of the disease and watch for side effects and changes in health.

The study also includes people whose cancer had already gotten worse after earlier treatment with pembrolizumab and enfortumab vedotin, which are cancer medicines used in advanced bladder and urinary tract cancer. The trial is designed to understand how well this treatment approach works and how safe it is for people with advanced or metastatic disease.

]]> Safety and Antitumor Activity of PF-08634404 Alone or with Enfortumab Vedotin in Adults with Locally Advanced or Metastatic Urothelial Cancer https://clinicaltrials.eu/trial/safety-and-antitumor-activity-of-pf-08634404-alone-or-with-enfortumab-vedotin-in-adults-with-locally-advanced-or-metastatic-urothelial-cancer/ Sun, 31 May 2026 04:02:43 +0000 https://clinicaltrials.eu/trial/safety-and-antitumor-activity-of-pf-08634404-alone-or-with-enfortumab-vedotin-in-adults-with-locally-advanced-or-metastatic-urothelial-cancer/ The study focuses on adults with Urothelial Cancer that is locally advanced or has spread to other parts of the body (metastatic). Participants receive either the investigational medicine PF-08634404 alone or together with the approved therapy Enfortumab Vedotin. Both medicines are given by an IV infusion, which means they are delivered directly into a vein.

The purpose of the study is to learn how well the new medicine works against the cancer and how safe it is for patients, both by itself and when combined with the other drug. Participants will attend regular visits where they receive the infusion in a series of treatment cycles, and doctors will check for any side effects and whether the cancer is responding.

Throughout the study, doctors will monitor participants for common side effects, track any changes in the size of the cancer, and take blood samples to understand how the medicine moves through the body. The overall goal is to find a dose that is effective while keeping side effects manageable.

]]> Study of Izalontamab Brengitecan Compared to Platinum-Based Chemotherapy for Patients with Metastatic Urothelial Cancer After Immunotherapy https://clinicaltrials.eu/trial/study-of-izalontamab-brengitecan-compared-to-platinum-based-chemotherapy-for-patients-with-metastatic-urothelial-cancer-after-immunotherapy/ Wed, 29 Apr 2026 15:08:14 +0000 https://clinicaltrials.eu/trial/study-of-izalontamab-brengitecan-compared-to-platinum-based-chemotherapy-for-patients-with-metastatic-urothelial-cancer-after-immunotherapy/ This study is looking at metastatic urothelial cancer, which is a cancer that started in the lining of the bladder or urinary tract and has spread to other parts of the body. The study will test a medicine called izalontamab brengitecan, which is also known by its code name BMS986507. This medicine will be compared to standard chemotherapy treatments that use platinum-based drugs. The platinum-based chemotherapy includes either cisplatin or carboplatin, which are given together with gemcitabine. The study also uses pegfilgrastim, which is a supportive medicine that helps protect the body during chemotherapy treatment.

The purpose of the study is first to find the right dose of izalontamab brengitecan to use, and then to see how well this medicine works compared to platinum-based chemotherapy in people whose cancer has gotten worse during or after treatment with immunotherapy. The study is designed for people who have already received immunotherapy treatment and whose cancer has continued to grow or spread despite this treatment. Participants in this study must be able to receive platinum-based chemotherapy and should not have had more than two previous types of treatment for their cancer that has spread.

The study will be done in two phases. In the first phase, researchers will determine the best dose of izalontamab brengitecan by looking at how safe it is and how well it works. In the second phase, participants will be randomly assigned to receive either izalontamab brengitecan or platinum-based chemotherapy, and the two treatments will be compared. The study will measure how long it takes for the cancer to get worse, how long participants live, how many people respond to treatment, and how long those responses last. The study will also look at how the treatments affect quality of life.

]]> Study of Livmoniplimab and Budigalimab Compared to Chemotherapy for Adults with Advanced Bladder Cancer https://clinicaltrials.eu/trial/study-of-livmoniplimab-and-budigalimab-compared-to-chemotherapy-for-adults-with-advanced-bladder-cancer/ Wed, 29 Apr 2026 15:02:56 +0000 https://clinicaltrials.eu/trial/study-of-livmoniplimab-and-budigalimab-compared-to-chemotherapy-for-adults-with-advanced-bladder-cancer/ This clinical trial is focused on studying a type of cancer called Metastatic Urothelial Carcinoma, which is a cancer that affects the bladder and other parts of the urinary system. The study is testing a new combination of treatments to see how effective they are compared to standard chemotherapy. The treatments being tested are called Livmoniplimab and Budigalimab. These are given through an intravenous infusion, which means they are delivered directly into the bloodstream through a vein.

The purpose of the study is to find the best dose of Livmoniplimab when used with Budigalimab and to see how well this combination works in patients who have already tried other treatments. The study will compare the new combination to traditional chemotherapy drugs, which include Paclitaxel, Docetaxel, and Gemcitabine. These chemotherapy drugs are also given through an intravenous infusion. The study will help determine if the new combination can improve the overall survival of patients, which means living longer without the cancer getting worse.

Participants in the study will receive either the new combination of Livmoniplimab and Budigalimab or one of the standard chemotherapy treatments. The study will last for up to 24 months, during which time the health of the participants will be closely monitored. The goal is to see if the new treatment can help patients live longer and have a better quality of life compared to the standard chemotherapy options. This study is important for finding new ways to treat Metastatic Urothelial Carcinoma and potentially improve outcomes for patients with this type of cancer.

]]> Study on Nivolumab and Ipilimumab for Patients with Advanced Urothelial Cancer After Initial Chemotherapy https://clinicaltrials.eu/trial/study-on-nivolumab-and-ipilimumab-for-patients-with-advanced-urothelial-cancer-after-initial-chemotherapy/ Wed, 29 Apr 2026 14:28:08 +0000 https://clinicaltrials.eu/trial/study-on-nivolumab-and-ipilimumab-for-patients-with-advanced-urothelial-cancer-after-initial-chemotherapy/ This clinical trial is focused on studying a type of cancer called urothelial cancer, which affects the urinary system, including the bladder. The trial is specifically for cases where the cancer is advanced and cannot be removed by surgery. The study is investigating the effectiveness of two medications, Nivolumab and Ipilimumab, used together as a maintenance therapy. These medications are given after patients have completed their initial chemotherapy treatment. Nivolumab and Ipilimumab are types of immunotherapy, which means they help the body’s immune system fight cancer.

The purpose of the study is to see if this combination of medications can help delay the progression of the cancer. Patients who participate in the study will receive the medications through an infusion, which is a way of delivering the drugs directly into the bloodstream. The study will monitor patients over a period to see how the cancer responds to the treatment and to check for any side effects. Some patients in the study may receive a placebo, which is a substance with no active medication, to compare the effects of the treatment.

Throughout the study, researchers will collect information on how long patients live without the cancer getting worse, overall survival rates, and any changes in the size of the cancer. They will also look at the quality of life reported by patients using questionnaires. The study aims to provide valuable insights into whether this treatment approach can offer benefits to patients with advanced urothelial cancer.

]]>